Conotoxins targeting neuronal voltage-gated sodium channel subtypes: Potential analgesics?

Toxins

Volumn 4, Issue 11, 2012, Pages 1236-1260

  Knapp, Oliver ^a   McArthur, Jeffrey R ^a   Adams, David J ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

conotoxin; O conotoxin; Analgesic; Nav1.3; Nav1.7; Nav1.8; Nav1.9; Nociception; Pain; voltage gated sodium channel

Indexed keywords

CONOTOXIN; LIDOCAINE; MU CONOTOXIN; MU CONOTOXIN BUIIIA; MU CONOTOXIN BUIIIB; MU CONOTOXIN BUIIIC; MU CONOTOXIN CNIIIA; MU CONOTOXIN CNIIIB; MU CONOTOXIN CNIIIC; MU CONOTOXIN GIIIA; MU CONOTOXIN GIIIB; MU CONOTOXIN GIIIC; MU CONOTOXIN KIIIA; MU CONOTOXIN PIIIA; MU CONOTOXIN SIIIA; MU CONOTOXIN SMIIIA; MU CONOTOXIN SXIIIA; MU CONOTOXIN SXIIIB; MU CONOTOXIN TIIIA; MUO CONOTOXIN; MUO CONOTOXIN MFVIA; MUO CONOTOXIN MRVIA; MUO CONOTOXIN MRVIB; OMEGA CONOTOXIN MVIIA; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.7; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.9; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIA; ANALGESIC ACTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; INFLAMMATORY PAIN; NERVOUS SYSTEM; NOCICEPTION; NONHUMAN; PAIN; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TOXIN ANALYSIS; TOXIN SYNTHESIS;

AMINO ACID SEQUENCE; ANALGESICS; ANIMALS; BINDING SITES; CONOTOXINS; CONUS SNAIL; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEURALGIA; NEURONS; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS; VOLTAGE-GATED SODIUM CHANNELS;

ANIMALIA;

EID: 84870567345     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4111236     Document Type: Review

References (146)

1. Hille, B.; Armstrong, C.M.; MacKinnon, R. Ion channels: from idea to reality. Nat. Med. 1999, 5, 1105-1109.
2. Payandeh, J.; Gamal El-Din, T.M.; Scheuer, T.; Zheng, N.; Catterall, W.A. The crystal structure of a voltage-gated sodium channel. Nature 2011, 475, 353-358.
3. Payandeh, J.; Gamal El-Din, T.M.; Scheuer, T.; Zheng, N.; Catterall, W.A. Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. Nature 2012, 486, 135-139.
4. Zhang, X.; Ren, W.; DeCaen, P.; Yan, C.; Tao, X.; Tang, L.; Wang, J.; Hasegawa, K.; Kumasaka, T.; He, J.; Wang, J.; Clapham, D.E.; Yan, N. Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature 2012, 486, 130-134.
5. Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57, 397-409.
6. Al-Sabi, A.; McArthur, J.; Ostroumov, V.; French, R.J. Marine toxins that target voltage-gated sodium channels. Mar. Drugs 2006, 4, 157-192.
7. Lee, C.H.; Ruben, P.C. Interaction between voltage-gated sodium channels and the neurotoxin, tetrodotoxin. Channels (Austin) 2008, 2, 407-412.
8. + channel isoform. Proc. Natl. Acad. Sci. USA 1989, 86, 8170-8174.
9. Satin, J.; Kyle, J.W.; Chen, M.; Bell, P.; Cribbs, L.L.; Fozzard, H.A.; Rogart, R.B. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science 1992, 256, 1202-1205.
10. Isom, L.L. Sodium channel beta subunits: anything but auxiliary. Neuroscientist 2011, 7, 42-54.
11. Meadows, L.; Malhotra, J.D.; Stetzer, A.; Isom, L.L.; Ragsdale, D.S. The intracellular segment of the sodium channel β1 subunit is required for its efficient association with the channel α subunit. J. Neurochem. 2001, 76, 1871-1878.
12. + channels interact with different molecular regions of the β1 subunit. J. Gen. Physiol. 2002, 120, 887-895.
13. Carter, G.T.; Sullivan, M.D. Antidepressants in pain management. Curr. Opin. Investig. Drugs 2002, 3, 454-458.
14. Reisner, L. Antidepressants for chronic neuropathic pain. Curr. Pain Headache Rep. 2003, 7, 24-33.
15. Bouhassira, D.; Lantéri-Minet, M.; Attal, N.; Laurent, B.; Touboul, C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008, 136, 380-387.
16. Jensen, M.P.; Chodroff, M.J.; Dworkin, R.H. The impact of neuropathic pain on health-related quality of life. Neurology 2007, 68, 1178-1182.
17. Dworkin, R.H.; Malone, D.C.; Panarites, C.J.; Armstrong, E.P.; Pham, S.V. Impact of post-therapeutic neuralgia and painful diabetic peripheral neuropathy on health care costs. J. Pain. 2010, 11, 360-368.
18. Akopian, A.N.; Souslova, V.; England, S.; Okuse, K.; Ogata, N.; Ure, J.; Smith, A.; Kerr, B.J.; McMahon, S.B.; Boyce, S.; Hill, R.; Stanfa, L.C.; Dickenson, A.H.; Wood, J.N. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat. Neurosci. 1999, 2, 541-548.
19. Black, J.A.; Cummins, T.R.; Plumpton, C.; Chen, Y.H.; Hormuzdiar, W.; Clare, J.J.; Waxman, S.G. Upregulation of a silent sodium channel after peripheral, but not central, nerve injury in DRG neurons. J. Neurophysiol. 1999, 82, 2776-2785.
20. Coward, K.; Plumpton, C.; Facer, P.; Birch, R.; Carlstedt, T.; Tate, S.; Bountra, C.; Anand, P. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain 2000, 85, 41-50.
21. Cummins, T.R.; Dib-Hajj, S.D.; Black, J.A.; Waxman, S.G. Sodium channels and the molecular pathophysiology of pain. Prog. Brain Res. 2000, 129, 3-19.
22. Cummins, T.R.; Waxman, S.G. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J. Neurosci. 1997, 17, 3503-3514.
23. + channel α-SNS in spinal sensory neurons following axotomy. Proc. Natl. Acad. Sci. USA 1996, 93, 14950-14954.
24. Dib-Hajj, S.D.; Black, J.A.; Cummins, T.R.; Kenney, A.M.; Kocsis, J.D.; Waxman, S.G. Rescue of α-SNS sodium channel expression in small dorsal root ganglion neurons after axotomy by nerve growth factor in vivo. J. Neurophysiol. 1998, 79, 2668-2676.
25. Dib-Hajj, S.D.; Fjell, J.; Cummins, T.R.; Zheng, Z.; Fried, K.; LaMotte, R.; Black, J.A.; Waxman, S.G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83, 591-600.
26. Fjell, J.; Cummins, T.R.; Davis, B.M.; Albers, K.M.; Fried, K.; Waxman, S.G.; Black, J.A. Sodium channel expression in NGF-overexpressing transgenic mice. J. Neurosci. Res. 1999, 57, 39-47.
27. + currents and inflammatory hyperalgesia. Proc. Natl. Acad. Sci. USA 1999, 96, 7645-7649.
28. + currents following axotomy of dorsal root ganglion neurons. J. Neurophysiol. 2002, 88, 650-658.
29. v1.8 (PN3/SNS) in a rat model of visceral pain. J. Neurosci. 2001, 21, 8690-8696.
30. Waxman, S.G.; Dib-Hajj, S.; Cummins, T.R.; Black, J.A. Sodium channels and pain. Proc. Natl. Acad. Sci. USA 1999, 96, 7635-7639.
31. Djouhri, L.; Fang, X.; Koutsikou, S.; Lawson, S.N. Partial nerve injury induces electrophysiological changes in conducting (uninjured) nociceptive and nonnociceptive DRG neurons: Possible relationships to aspects of peripheral neuropathic pain and paresthesias. Pain 2012, 153, 1824-1836.
32. Waxman, S.G.; Kocsis, J.; Black, J.A. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is re-expressed following axotomy. J. Neurophysiol. 1994, 72, 466-470.
33. Hains, B.C.; Saab, C.Y.; Klein, J.P.; Craner, M.J.; Waxman, S.G. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J. Neurosci. 2004, 24, 4832-4839.
34. Black, J.A.; Lui, S.; Tanaka, M.; Cummins, T.R.; Waxman, S.G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 2004, 108, 237-247.
35. Lampert, A.; Hains, B.C.; Waxman, S.G. Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury. Exp. Brain Res. 2006, 174, 660-666.
36. v1.8 in DRG neurons following motor fiber injury. Pain 2010, 151, 266-279.
37. v1.8 in trigeminal neuralgia. Neuroscience 2009, 164, 573-577.
38. Yoshida, S. Tetrodotoxin-resistant sodium channels. Cell. Mol. Neurobiol. 1994, 14, 227-244.
39. Momin, A.; Wood, J.N. Sensory neuron voltage-gated sodium channels as analgesic drug targets. Curr. Opin. Neurobiol. 2008, 18, 383-388.
40. v1.3 null mutant mice. Mol. Pain 2006, 2, 33.
41. Klugbauer, N.; Lacinova, L.; Flockerzi, V.; Hofmann, F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 1995, 14, 1084-1090.
42. Felts, P.A.; Yokoyama, S.; Dib-Hajj, S.; Black, J.A.; Waxman, S.G. Sodium channel α-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): different expression patterns in developing rat nervous system. Brain Res. Mol. Brain Res. 1997, 45, 71-82.
43. Sangameswaran, L.; Fish, L.M.; Koch, B.D.; Rabert, D.K.; Delgado, S.G.; Ilnicka, M.; Jakeman, L.B.; Novakovic, S.; Wong, K.; Sze, P.; Tzoumaka, E.; Stewart, G.R.; Herman, R.C.; Chan, H.; Eglen, R.M.; Hunter, J.C. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J. Biol. Chem. 1997, 272, 14805-14809.
44. Toledo-Aral, J.J.; Moss, B.L.; He, Z.J.; Koszowski, A.G.; Whisenand, T.; Levinson, S.R.; Wolf, J.J.; Silos-Santiago, I.; Halegoua, S.; Mandel, G. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc. Natl. Acad. Sci. USA 1997, 94, 1527-1532.
45. Theile, J.W.; Cummins, T.R. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front. Pharmacol. 2011, 2, 54.
46. v1.8 peripheral nerve sodium channels. J. Neurosci. 2001, 21, 7909-7918.
47. Waxman, S.G.; Dib-Hajj, S. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol. Med. 2005, 11, 555-562.
48. Fertleman, C.R.; Baker, M.D.; Parker, K.A.; Moffatt, S.; Elmslie, F.V.; Abrahamsen, B.; Ostman, J.; Klugbauer, N.; Wood, J.N.; Gardiner, R.M.; Rees, M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 2006, 52, 767-774.
49. v1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 2007, 71, 311-319.
50. Cox, J.J.; Reimann, F.; Nicholas, A.K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al-Gazali, L.; Hamamy, H.; Valente, E.M.; Gorman, S.; Williams, R.; McHale, D.P.; Wood, J.N.; Gribble, F.M.; Woods, C.G. An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444, 894-898.
51. Lampert, A.; O'Reilly, A.O.; Reeh, P.; Leffler, A. Sodium channelopathies and pain. Pflugers Arch. 2010, 460, 249-263.
52. v1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. Anesth. Analg. 2009, 109, 951-958.
53. v1.7 is the predominant sodium channel in rodent olfactory sensory neurons. Mol. Pain 2011, 7, 32.
54. v1.7 cause anosmia. Nature 2011, 472, 186-190.
55. v1.7 in the normal and injured rodent olfactory system indicates a critical role in olfaction, pheromone sensing and immune function. Channels (Austin) 2012, 6, 103-110.
56. Gold, M.S.; Weinreich, D.; Kim, C.S.; Wang, R.; Treanor, J.; Porreca, F.; Lai, J. Redistribution of Nav1.8 in uninjured axons enables neuropathic pain. J. Neurosci. 2003, 23, 158-166.
57. v1.8 is essential for pain at low temperatures. Nature 2007, 447, 855-858.
58. Coward, K.; Jowett, A.; Plumpton, C.; Powell, A.; Birch, R.; Tate, S.; Bountra, C.; Anand, P. Sodium channel β1 and β2 subunits parallel SNS/PN3 α-subunit changes in injured human sensory neurons. Neuroreport 2001, 12, 483-488.
59. v1.3 sodium channels, expressed in mammalian cells, by auxiliary β1, β2 and β3 subunits. Neuroscience 2002, 114, 745-753.
60. v1.8. Mol. Pain 2005, 1, 24.
61. v1.9. Toxins. 2012, 4, 620-632.
62. v1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc. Natl. Acad. Sci. USA 2006, 103, 17030-17035.
63. v1.8 in NGF-induced hyperalgesia, but not neuropathic pain. Neuroreport 2001, 12, 3077-3080.
64. v1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain 2002, 96, 269-277.
65. v1.9 knockout mice. Behav. Brain. Res. 2010, 208, 149-157.
66. Cummins, T.R.; Dib-Hajj, S.D.; Black, J.A.; Akopian, A.N.; Wood, J.N.; Waxman, S.G. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J. Neurosci. 1999, 19, RC43.
67. + current affects resting potential and response to depolarization in simulated spinal sensory neurons. J. Neurophysiol. 2001, 86, 1351-1364.
68. + current regulates excitability in mouse and rat small diameter sensory neurones. J. Physiol. 2003, 548, 373-382.
69. v1.9 to sensory transmission and nociceptive behavior. Proc. Natl. Acad. Sci. USA 2005, 102, 9382-9387.
70. v1.9 is an effector of peripheral inflammatory pain hypersensitivity. J. Neurosci. 2006, 26, 12852-12860.
71. v1.9, generates inhibitory effects on complete Freund's adjuvant-induced inflammatory pain in rat. PLoS One 2011, 6, e19865.
72. Oliver, B.M. Conus venom peptides: reflections from the biology of clades and species. Annu. Rev. Ecol. Syst. 2002, 33, 25-47.
73. Terlau, H.; Oliver, B.M. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 2004, 84, 41-68.
74. Rice, R.D.; Halstead, B.W. Report of fatal cone shell sting by Conus geographus Linnaeus. Toxicon 1968, 5, 223-224.
75. Davis, J.; Jones, A.; Lewis, R.J. Remarkable inter-and intra-species complexity of conotoxins revealed by LC/MS. Peptides 2009, 30, 1222-1227.
76. Hui, K.; Lipkind, G.; Fozzard, H.A.; French, R.J. Electrostatic and steric contributions to block of the skeletal muscle sodium channel by μ-conotoxin. J. Gen. Physiol. 2002, 119, 45-54.
77. v channels by interfering with their voltage sensors in domain-2. Channels (Austin) 2007, 1, 253-262.
78. Gilly, W.F.; Richmond, T.A.; Duda, T.F., Jr.; Elliger, C.; Lebaric, Z.; Schulz, J.; Bingham, J.P.; Sweedler, J.V. A diverse family of novel peptide toxins from an unusual cone snail, Conus californicus. J. Exp. Biol. 2011, 214, 147-161.
79. Liu, J.; Wu, Q.; Pi, C.; Zhao, Y.; Zhou, M.; Wang, L.; Chen, S.; Xu, A. Isolation and characterization of a T-superfamily conotoxin from Conus litteratus with targeting tetrodotoxin-sensitive sodium channels. Peptides 2007, 28, 2313-2319.
80. Leipold, E.; Hansel, A.; Olivera, B.M.; Terlau, H.; Heinemann, S.H. Molecular interaction of 8-conotoxins with voltage-gated sodium channels. FEBS Lett. 2005, 579, 3881-3884.
81. Craik, D.J.; Daly, N.L.; Waine, C. The cystine knot motif in toxins and implications for drug design. Toxicon 2001, 39, 43-60.
82. Fainzilber, M.; van der Schors, R.; Lodder, J.C.; Li, K.W.; Geraerts, W.P.; Kits, K.S. New sodium channel-blocking conotoxins also affect calcium currents in Lymnaea neurons. Biochemistry 1995, 34, 5364-5371.
83. Hasson, A.; Shon, K.J.; Olivera, B.M.; Spira, M.E. Alterations of voltage-activated sodium current by a novel conotoxin from the venom of Conus gloriamaris. J. Neurophysiol. 1995, 73, 1295-1301.
84. Shichor, I.; Fainzilber, M.; Pelhate, M.; Malecot, C.O.; Zlotkin, E.; Gordon, D. Interactions of 8-conotoxins with alkaloid neurotoxins reveal differences between the silent and effective binding sites on voltage-sensitive sodium channels. J. Neurochem. 1996, 167, 2451-2460.
85. + channels but not in skeletal and cardiac muscles. J. Biol. Chem. 2004, 279, 4680-4685.
86. Sudarslal, S.; Majumdar, S.; Ramasamy, P.; Dhawan, R.; Pal, P.P.; Ramaswami, M.; Lala, A.K.; Sikdar, S.K.; Sarma, S.P.; Krishnan, K.S.; Balaram, P. Sodium channel modulating activity in a δ-conotoxin from an Indian marine snail. FEBS Lett. 2003, 553, 209-212.
87. Sarma, S.P.; Kumar, G.S.; Sudarslal, S.; Iengar, P.; Ramasamy, P.; Sikdar, S.K.; Krishnan, K.S.; Balaram, P. Solution structure of δ-Am2766: a highly hydrophobic δ-conotoxin from Conus amadis that inhibits inactivation of neuronal voltage-gated sodium channels. Chem. Biodivers. 2005, 2, 535-556.
88. Wang, L.; Lui, J.; Pi, C.; Zeng, X.; Zhou, M.; Jiang, X.; Chen, S.; Ren, Z.; Xu, A. Identification of a novel M-superfamily conotoxin with the ability to enhance tetrodotoxin sensitive sodium currents. Arch. Toxicol. 2009, 83, 925-932.
89. v1.2, 1.6 and 1.7. Biochem. Pharmacol. 2008, 75, 2334-2344.
90. + channels. J. Biol. Chem. 2003, 278, 8717-8724.
91. Spence, I.; Gillessen, D.; Gregson, R.P.; Quinn, R.J. Characterization of the neurotoxic constituents of Conus geographus (L) venom. Life Sci. 1977, 21, 1759-1769.
92. Cruz, L.J.; Gray, W.R.; Olivera, B.M.; Zeikus, R.D.; Kerr, L.; Yoshikami, D.; Moczydlowski, E. Conus geographus toxins that discriminate between neuronal and muscle sodium channels. J. Biol. Chem. 1985, 260, 9280-9288.
93. Becker, S.; Prusak-Sochaczewski, E.; Zamponi, G.; Beck-Sickinger, A.G.; Gordon, R.D.; French, R.J. Action of derivatives of μ-conotoxin GIIIA on sodium channels. Single amino acid substitutions in the toxin separately affect association and dissociation rates. Biochemistry 1992, 31, 8229-8238.
94. Wakamatsu, K.; Kohda, D.; Hatanaka, H.; Lancelin, J.M.; Ishida, Y.; Oya, M.; Nakamura, H.; Inagaki, F.; Sato, K. Structure-activity relationships of μ-conotoxin GIIIA: structure determination of active and inactive sodium channel blocker peptides by NMR and simulated annealing calculations. Biochemistry 1992, 31, 12577-12584.
95. Hill, J.M.; Alewood, P.F.; Craik, D.J. Three-dimensional solution structure of μ-conotoxin GIIIB, a specific blocker of skeletal muscle sodium channels. Biochemistry 1996, 35, 8824-8835.
96. Nielsen, K.J.; Watson, M.; Adams, D.J.; Hammarström, A.K.; Gage, P.W.; Hill, J.M.; Craik, D.J.; Thomas, L.; Adams, D.; Alewood, P.F.; Lewis, R.J. Solution structure of μ-conotoxin PIIIA, a preferential inhibitor of persistent tetrodotoxin-sensitive sodium channels. J. Biol. Chem. 2002, 277, 27247-27255.
97. Keizer, D.W.; West, P.J.; Lee, E.F.; Yoshikami, D.; Olivera, B.M.; Bulaj, G.; Norton, R.S. Structural basis for tetrodotoxin-resistant sodium channel binding by μ-conotoxin SmIIIA. J. Biol. Chem. 2003, 278, 46805-46813.
98. v 1.2/1.4) and reveals unusual activity on neuronal nicotinic acetylcholine receptors. Br. J. Pharmacol. 2012, 166, 1654-1668.
99. Shon, K.J.; Olivera, B.M.; Watkins, M.; Jacobsen, R.B.; Gray, W.R.; Floresca, C.Z.; Cruz, L.J.; Hillyard, D.R.; Brink, A.; Terlau, H.; Yoshikami, D. μ-Conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes. J. Neurosci. 1998, 18, 4473-4481.
100. McArthur, J.R.; Simgh, G.; McMaster, D.; Winkfein, R.; Tieleman, D.P.; French, R.J. Interactions of key charged residues contributing to selective block of neuronal sodium channels by μ-conotoxin KIIIA. Mol. Pharmacol. 2011, 80, 573-584.
101. Zhang, M.M.; Green, B.R.; Catlin, P.; Fiedler, B.; Azam, L.; Chadwick, A.; Terlau, H.; McArthur, J.R.; French, R.J.; Gulyas, J.; Rivier, J.E.; Smith, B.J.; Norton, R.S.; Olivera, B.M.; Yoshikami, D.; Bulaj, G. Structure/function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J. Biol. Chem. 2007, 282, 30699-30706.
102. Zhang, M.M.; Han, T.S.; Olivera, B.M.; Bulaj, G.; Yoshikami, D. μ-Conotoxin KIIIA derivatives with divergent affinities versus efficacies in blocking voltage-gated sodium channels. Biochemistry 2010, 49, 4804-4812.
103. Green, B.R.; Catlin, P.; Zhang, M.M.; Fiedler, B.; Bayudan, W.; Morrison, A.; Norton, R.S.; Smith, B.J.; Yoshikami, D.; Olivera, B.M.; Bulaj, G. Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity. Chem. Biol. 2007, 14, 399-407.
104. Leipold, E.; Markgraf, R.; Miloslavina, A.; Kijas, M.; Schirmeyer, J.; Imhof, D.; Heinemann, S.H. Molecular determinants for the subtype specificity of μ-conotoxin SIIIA targeting neuronal voltage-gated sodium channels. Neuropharmacology 2011, 61, 105-111.
105. Yao, S.; Zhang, M.M.; Yoshikami, D.; Azam, L.; Olivera, B.M.; Bulaj, G.; Norton, R.S. Structure, dynamics, and selectivity of the sodium channel blocker μ-conotoxin SIIIA. Biochemistry 2008, 47, 10940-10949.
106. McArthur, J.R.; Ostroumov, V.; Al-Sabi, A.; McMaster, D.; French, R.J. Multiple, distributed interactions of μ-conotoxin PIIIA associated with broad targeting among voltage-gated sodium channels. Biochemistry 2011, 50, 116-124.
107. v1.1 through 1.8 identify those responsible for action potentials in sciatic nerve. Proc. Natl. Acad. Sci. USA 2011, 108, 10302-10307.
108. Markgraf, R.; Leipold, E.; Schirmeyer, J.; Paolini-Bertrand, M.; Hartley, O.; Heinemann, S.H. Mechanism and molecular basis for the sodium channel subtype specificity of μ-conopeptide CnIIIC. Br. J. Pharmacol. 2012, 167, 576-586.
109. Han, T.S.; Teichert, R.W.; Olivera, B.M.; Bulaj, G. Conus venoms-a rich source of peptide-based therapeutics. Curr. Pharm. Des. 2008, 14, 2462-2479.
110. McArthur, J.R.; Singh, G.; O'Mara, M.L.; McMaster, D.; Ostroumov, V.; Tieleman, D.P.; French, R.J. Orientation of μ-conotoxin PIIIA in a sodium channel vestibule, based on voltage dependence of its binding. Mol. Pharmacol. 2011, 80, 219-227.
111. + channels. J. Biol. Chem. 2000, 275, 27551-27558.
112. Choudhary, G.; Aliste, M.; Tieleman, D.P.; French, R.J.; Dudley, S.C., Jr. Docking of μ-conotoxin GIIIA in the sodium channel outer vestibule. Channels (Austin) 2007, 1, 344-352.
113. + channel localized by mutant cycle analysis. Biochemistry 1998, 37, 4407-4419.
114. v 1.4. Angew. Chem. Int. Ed. Engl. 2012, 51, 4058-4061.
115. Walewska, A.; Zhang, M.M.; Skalicky, J.J.; Yoshikami, D.; Olivera, B.M.; Bulaj, G. Integrated oxidative folding of cysteine/selenocysteine containing peptides: improving chemical synthesis of conotoxins. Angew. Chem. Int. Ed. Engl. 2009, 48, 2221-2224.
116. Besse, D.S.; Fourmy, D.; Diercks, T.; Kessler, H.; Moroder, L. The redox potential of selenocystine in unconstrained cyclic peptides. Angew. Chem. Int. Ed. 1997, 36, 883-885.
117. Norton, R.S. μ-Conotoxins as leads in the development of new analgesics. Molecules 2010, 15, 2825-2844.
118. Khoo, K.K.; Wilson, M.J.; Smith, B.J.; Zhang, M.M.; Gulyas, J.; Yoshikami, D.; Rivier, J.E.; Bulaj, G.; Norton, R.S. Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA. J. Med. Chem. 2011, 54, 7558-7566.
119. Stevens, M.; Peigneur, S.; Dyubankova, N.; Lescrinier, E.; Herdewijn, P.; Tytgat, J. Design of bioactive peptides from naturally occurring μ-conotoxin structures. J. Biol. Chem. 2012, 37, 31382-31392.
120. Khoo, K.K.; Feng, Z.P.; Smith, B.J.; Zhang, M.M.; Yoshikami, D.; Olivera, B.M.; Bulaj, G.; Norton, R.S. Structure of the analgesic μ-conotoxin KIIIA and effects on the structure and function of disulfide deletion. Biochemistry 2009, 48, 1210-1219.
121. Schroeder, C.I.; Adams, D.; Thomas, L.; Alewood, P.F.; Lewis, R.J. N-and C-terminal extensions of μ-conotoxins increase potency and selectivity for neuronal sodium channels. Biopolymers 2012, 98, 161-165.
122. Han, T.S.; Zhang, M.M.; Walewska, A.; Gruszczynski, P.; Robertson, C.R.; Cheatham, T.E.; Yoshikami, D.; Olivera, B.M.; Bulaj, G. Structurally minimized μ-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics. ChemMedChem. 2009, 4, 406-614.
123. Stürzebecher, A.S.; Hu, J.; Smith, E.S.; Frahm, S.; Santos-Torres, J.; Kampfrath, B.; Auer, S.; Lewin, G.R.; Ibañez-Tallon, I. An in vivo tethered toxin approach for the cell-autonomous inactivation of voltage-gated sodium channel currents in nociceptors. J. Physiol. 2010, 588, 1695-1707.
124. v1.8 and has a long-lasting analgesic activity. Biochemistry 2006, 45, 7404-7414.
125. Daly, N.L.; Ekberg, J.A.; Thomas, L.; Adams, D.J.; Lewis, R.J.; Craik, D.J. Structures of μO-conotoxins from Conus marmoreus. Inhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian sensory neurons. J. Biol. Chem. 2004, 279, 25774-25782.
126. Terlau, H.; Stocker, M.; Shon, K.J.; McIntosh, J.M.; Olivera, B.M. μO-conotoxin MrVIA inhibits mammalian sodium channels, but not through site I. J. Neurophysiol. 1996, 76, 1423-1429.
127. v1.8 by the analgesic gating modifier μO-conotoxin MrVIB. J. Pharmacol. Exp. Ther. 2011, 338, 687-693.
128. Zorn, S.; Leipold, E.; Hansel, A.; Bulaj, G.; Olivera, B.M.; Terlau, H.; Heinemann, S.H. The μO-conotoxin MrVIA inhibits voltage-gated sodium channels by associating with domain-3. FEBS Lett. 2006, 580, 1360-1364.
129. v1.2 chimeras and inhibition by μO-conotoxin MrVIB. Br. J. Pharmacol. 2012, 166, 2148-2160.
130. Bosmans, F.; Puopolo, M.; Martin-Eauclaire, M.F.; Bean, B.P.; Swartz, K.J. Functional properties and toxin pharmacology of a dorsal root ganglion sodium channel viewed through its voltage sensors. J. Gen. Physiol. 2011, 138, 59-72.
131. Bosmans, F.; Martin-Eauclaire, M.F.; Swartz, K.J. Deconstructing voltage sensor function and pharmacology in sodium channels. Nature 2008, 456, 202-208.
132. Bosmans, F.; Swartz, K.J. Targeting voltage sensors in sodium channels with spider toxins. Trends Pharmacol. Sci. 2010, 31, 175-182.
133. Vetter, I.; Dekan, Z.; Knapp, O.; Adams, D.J.; Alewood, P.F.; Lewis, R.J. Isolation, characterization and total regioselective synthesis of the novel μO-conotoxin MfVIA from Conus magnificus that targets voltage-gated sodium channels. Biochem. Pharmacol. 2012, 4, 540-548.
134. McIntosh, J.M.; Hasson, A.; Spira, M.E.; Gray, W.R.; Li, W.; Marsh, M.; Hillyard, D.R.; Olivera, B.M. A new family of conotoxins that blocks voltage-gated sodium channels. J. Biol. Chem. 1995, 270, 16796-16802.
135. Pi, C.; Lui, J.; Wang, L.; Jiang, X.; Liu, Y.; Peng, C.; Chen, S.; Xu, A. Soluble expression, purification and functional identification of a disulfide-rich conotoxin derived from Conus litteratus. J. Biotechnol. 2007, 128, 184-193.
136. Wang, L.; Pi, C.; Liu, J.; Chen, S.; Peng, C.; Sun, D.; Zhou, M.; Xiang, H.; Ren, Z.; Xu, A. Identification and characterization of a novel O-superfamily conotoxin from Conus litteratus. J. Pept. Sci. 2008, 14, 1077-1083.
137. Lewis, R.J.; Dutertre, S.; Vetter, I.; Christie, M.J. Conus venom peptide pharmacology. Pharmacol. Rev. 2012, 64, 259-298.
138. de Araujo, A.D.; Callaghan, B.; Nevin, S.T.; Daly, N.L.; Craik, D.J.; Moretta, M.; Hopping, G.; Christie, M.J.; Adams, D.J.; Alewood, P.F. Total synthesis of the analgesic conotoxin MrVIB through selenocysteine-assisted folding. Angew. Chem. Int. Ed. Engl. 2011, 50, 6527-6529.
139. Ekberg, J.; Adams, D.J. Neuronal voltage-gated sodium channel subtypes: key roles in inflammatory and neuropathic pain. Int. J. Biochem. Cell. Biol. 2006, 38, 2005-2010.
140. Miljanich, G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 2004, 11, 3029-3040.
141. Staats, P.S.; Yearwood, T.; Charapata, S.G.; Presley, R.W.; Wallace, M.S.; Byas-Smith, M.; Fisher, R.; Bryce, D.A.; Mangieri, E.A.; Luther, R.R.; Mayo, M.; McGuire, D.; Ellis, D. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004, 291, 63-70.
142. Stix, G. A toxin against pain. Sci. Am. 2005, 292, 70-75.
143. v3.1 by ProTxII. Toxicon 2010, 56, 624-636.
144. Sokolov, S.; Kraus, R.L.; Scheuer, T.; Catterall, W.A. Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II. Mol. Pharmacol. 2008, 73, 1020-1028.
145. Siemens, J.; Zhou, S.; Piskorowski, R.; Nikai, T.; Lumpkin, E.A.; Basbaum, A.I.; King, D.; Julius, D. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 2006, 444, 208-212.
146. Clark, R.J.; Jensen, J.; Nevin, S.T.; Callaghan, B.P.; Adams, D.J.; Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. Engl. 2010, 49, 6545-6548.